Department of Biological Sciences, Hunter College at City University of New York, New York, United States.
Department of Ophthalmology, Margaret Dyson Vision Research Institute, Weill Cornell Medicine, New York, United States.
Elife. 2020 May 19;9:e51185. doi: 10.7554/eLife.51185.
Recently evolved alleles of Apolipoprotein L-1 () provide increased protection against African trypanosome parasites while also significantly increasing the risk of developing kidney disease in humans. APOL1 protects against trypanosome infections by forming ion channels within the parasite, causing lysis. While the correlation to kidney disease is robust, there is little consensus concerning the underlying disease mechanism. We show in human cells that the APOL1 renal risk variants have a population of active channels at the plasma membrane, which results in an influx of both Na and Ca. We propose a model wherein APOL1 channel activity is the upstream event causing cell death, and that the activate-state, plasma membrane-localized channel represents the ideal drug target to combat APOL1-mediated kidney disease.
最近进化的载脂蛋白 L-1(APOL1)等位基因提供了对非洲锥虫寄生虫的更大保护,同时也显著增加了人类罹患肾脏疾病的风险。APOL1 通过在寄生虫内部形成离子通道来保护免受锥虫感染,导致溶解。尽管与肾脏疾病的相关性很强,但对于潜在的疾病机制仍存在共识。我们在人类细胞中表明,APOL1 肾脏风险变体在质膜上具有活性通道群体,这导致 Na 和 Ca 的流入。我们提出了一个模型,其中 APOL1 通道活性是导致细胞死亡的上游事件,而激活状态、质膜定位的通道代表了对抗 APOL1 介导的肾脏疾病的理想药物靶点。